** Shares of LAVA Therapeutics LVTX.O rise 27.4% to $1.20 premarket, after drug developer says it is evaluating strategic options, including a potential sale or merger
** Co says it will continue to enroll patients in the early-stage clinical study of LAVA-1266 for treating hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome
** Co also has implemented a restructuring plan, which includes a workforce reduction of about 30% to reduce costs and conserve cash
** As of Dec 31, 2023, co had 35 full-time employees - SEC filing
** Co estimates it will incur $500,000 in one-time costs related to the workforce reduction in Q1 2025
** LVTX had $76.6 mln in cash as of Dec 31, 2024
** LVTX fell 45.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.